Search

Displaying results 1921 - 1930 of 10000 in total
  1. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    It was developed by Novartis and was granted FDA approval on November 15, 2019. … [L10097] While crizanlizumab received conditional marketing authorization from the EMA in October 2020, this approval was revoked in August 2023 due to concerns over the efficacy and safety of the drug

  2. Drug

    Decitabine

    go.drugbank.com/drugs/DB01262
    ApprovedInvestigational

    [L14962] It is also available as an oral combination product together with the cytidine deaminase inhibitor [cedazuridine]. … [A2263, A2264, A2265, A215317, L14962] Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006.

  3. Drug

    Dihydralazine

    go.drugbank.com/drugs/DB12945
    ApprovedWithdrawn

    Dihydralazine is under investigation in clinical trial NCT00311974 (The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals).

    Categories: Arteriolar Smooth Muscle, Agents Acting On
  4. Drug

    Propanoic acid

    go.drugbank.com/drugs/DB03766
    ApprovedInvestigationalVet approvedWithdrawn

    Sodium propionate was previously approved in Canada as an active ingredient in Amino-Cerv (used to treat inflammation or injury of the cervix). … Its use as a food additive is also approved in Europe. Sodium propionate is is prepared by neutralizing propionic acid with sodium hydroxide.

  5. Drug

    Dicoumarol

    go.drugbank.com/drugs/DB00266
    Approved

    In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases. … Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.

  6. Drug

    Fesoterodine

    go.drugbank.com/drugs/DB06702
    Approved

    Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.

  7. Drug

    Asparagine

    go.drugbank.com/drugs/DB00174
    ApprovedNutraceuticalWithdrawn

    (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed) … A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from aspartic acid and ammonia by asparagine synthetase.

    Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSION
  8. Drug

    Rozanolixizumab

    go.drugbank.com/drugs/DB14919
    ApprovedInvestigational

    [A260207] AChR is vital for signal transduction in the neuromuscular junctions (NMJ) by generating muscle end plate potentials to propagate action potential. … an action potential.

  9. Drug

    Latanoprostene bunod

    go.drugbank.com/drugs/DB11660
    Approved

    Conversely however, latanoprostene bunod integrates an NO-donating moiety in lieu of the isopropyl ester typically found in latanoprost. … In comparison, both latanoprost and latanoprostene bunod contain a latanoprost acid backbone.

  10. Drug

    Eucalyptol

    go.drugbank.com/drugs/DB03852
    ApprovedInvestigationalNutraceutical

    Eucalyptol is an ingredient in many brands of mouthwash and cough suppressant. It controls airway mucus hypersecretion and asthma via anti-inflammatory cytokine inhibition. … Eucalyptol is an effective treatment for nonpurulent rhinosinusitis. Eucalyptol reduces inflammation and pain when applied topically. It kills leukaemia cells in vitro.

    Categories: Compounds used in a research, industrial, or household setting